Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy

BACKGROUND: There is great interest in finding ways to identify patients who will develop toxicity to cancer therapies. This has become especially pressing in the era of immune therapy, where toxicity can be long-lasting and life-altering, and primarily comes in the form of immune-related adverse ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Weidhaas, Joanne, Marco, Nicholas, Scheffler, Aaron W, Kalbasi, Anusha, Wilenius, Kirk, Rietdorf, Emily, Gill, Jaya, Heilig, Mara, Desler, Caroline, Chin, Robert K, Kaprealian, Tania, McCloskey, Susan, Raldow, Ann, Raja, Naga P, Kesari, Santosh, Carrillo, Jose, Drakaki, Alexandra, Scholz, Mark, Telesca, Donatello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804679/
https://www.ncbi.nlm.nih.gov/pubmed/35115362
http://dx.doi.org/10.1136/jitc-2021-003625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804679/
https://www.ncbi.nlm.nih.gov/pubmed/35115362
http://dx.doi.org/10.1136/jitc-2021-003625

Ejemplares similares